|  |  |  |
| --- | --- | --- |
| Clinical Variable | Type of Variable | Definition |
| Age | Numeric | Age of patient in years |
| Buffa Hypoxia Score | Numeric | Gene expression-based signatures developed to quantify oxygen content in a tumor. (Buffa et al., 2010). |
| History of Neoadjuvant Treatment | Categorical  (No = 1; Yes = 2) | Treatment given for cancer before the main treatment.(*NCI Dictionary of Cancer Terms*, 2011). |
| ICD Histology | Categorical  (Acina cell carcinoma = 1; adenocarcinoma = 2; infiltrate\_duel\_carc = 3; mixed adenocarcinoma = 4; mucinous adenocarcinoma = 5; signet ring cell carc. = 6) | Codes to identify site (topography) and the histology (morphology) of neoplasms. (Allen, 1991). |
| Prior Diagnosis | Categorical  (1 = No; 2 = Yes) | Patients with a prior diagnosis |
| New Tumor After Initial Diagnosis | Categorical  (1 = No; 2 = Yes) | Persistence of tumor after initial treatment. |
| Pathological Node Stage | Categorical  (1 = cancer in lymph nodes  0 = cancer not in lymph nodes) | Cancer spread to lymph nodes.  (*Cancer Staging - NCI*, 2015) |
| Pathological Tumor Stage | Categorical  (T2A = Tumor is between 2-5 cm across and in either half or less of the prostate.  T2B = Tumor is between 2-5 cm across and in either half or more of the prostate  T2C = Tumor is between 2-5 cm across and in both sides of prostate  T3A = Tumor is more than 5cm across in either half or less of the prostate.  T4 = Tumor is of other size and spreading into other tissues) | Size of the cancer and how far it has spread into nearby tissue.  (Canadian Cancer Society, 2021; *Cancer Staging - NCI*, 2015) |
| Neoplasm Cancer Status | Categorical  (1 = Tumor free; 2 = With tumor) | Status of abnormal tumor growth.  (*NCI Dictionary of Cancer Terms*, 2011) |
| Radiation Therapy | Categorical  (1 = No; 2 = Yes) | Individuals exposed to radiation therapy treatment |
| Ragnum Hypoxia Score | Numeric | Prostate cancer specific hypoxia gene signatures developed to assess tumor oxygen levels.  (Ragnum et al., 2015; Yang et al., 2018) |
| Winter Hypoxia Score | Numeric | Gene expression signatures developed to quantify tumor oxygen levels across cancer types. (Winter et al., 2007) |
| Aneuploidy Score | Numeric | Measure the degree of aneuploidy (abnormal number of chromosomes) in a cell or tumor (A. M. Taylor et al., 2018). |
| MSI Sensor Score | Numeric | Determines the genomic instability by gauging the level of microsatellite instability of tumors. (Niu et al., 2014). |
| MSI mantis score | Numeric | Method for predicting microsatellite instability (MSI) status in tumor cells.  (Ye et al., 2023) |
| Tissue Source Site | Categorical  (1 = Biotech & Pharmaceutical company  2 = Hospital  3 = Research Centre  4 = University | Site where blood, tissues and patient metadata are obtained (Cerami et al., 2012). |
| Tumor Type | Categorical  (1 = Prostate adenocarcinoma acinar  2 = Prostate adenocarcinoma other subtype) | The morphologic changes of prostate carcinoma variants.  (Cerami et al., 2012; Li & Wang, 2016) |
| Tumor Mutation Burden | Numeric | Total number of somatic non-synonymous mutations present within the cancer genome. (Budczies et al., 2024). |
| Fraction of Genome Altered | Numeric | Proportion of tumor genome altered by genetic mutation. (Cerami et al., 2012; Plantalech, 2018) |
| Mutation Count | Numeric | Count of mutations found in the tumor genome. (Cerami et al., 2012; Plantalech, 2018) |
| PFS Months | Numeric | Duration (months) where cancer ceases progression. (Gyawali et al., 2022; Lebwohl et al., 2009). |
| PFS Status | Categorical  (0 = Censored; 1 = Progression) | Indicators to determine whether cancer progressed (1) or no information about cancer status (0). |